What an endotoxin limit is, and why sterile is not enough

Two claims, not one

Federal regulation treats these as separate properties, and the wording gives it away. For each batch of a drug product purporting to be sterile and or pyrogen-free, there has to be appropriate laboratory testing to determine conformance to those requirements, with written test procedures that are followed.

A pyrogen is a substance that produces a fever. Endotoxins are one kind of pyrogen and not the only kind, which is visible in the regulator's own phrase for the others: non-endotoxin pyrogens.

The practical difference is that killing or excluding organisms is one problem and removing what they leave behind is another. FDA's guidance on the subject treats endotoxin removal as its own manufacturing step, alongside the contamination that can arrive in raw materials, in materials partway through production, and in the finished product.

A page that says sterile has answered one of the two questions.

The limit is calculated, not looked up

This is the fact that changes how an endotoxin claim reads, and it comes from the agency explaining why it withdrew something.

An older FDA guidance carried a table of endotoxin limits. The agency says that table is out of date, because the number of dosage regimes and drug strengths has increased since it was published. The appropriate way to establish a limit is now to use the calculation methods in the compendial or standards documents.

The agency goes further. Limits printed in a monograph may also fail to account for current product strengths or dosage regimes, so those should be checked with the same calculations.

Read what that implies. An endotoxin limit is not a property of the substance. It is derived from how much of the product a person receives, which means the same material can sit inside the limit at one amount and outside it at another.

One more rule sits on top for a finished product with several components. The overall limit for a product given by injection should not exceed the overall threshold limit in the compendial chapter, whatever the limits on the individual components. Products given by other routes can be governed by a different calculation entirely.

So a result reading pass, with no limit printed beside it, has not told you what it passed.

The product can hide the endotoxin from the test

Endotoxin assays are affected by the thing being tested. The guidance calls this interference and enhancement, and most of its practical advice is about working around it.

The usual workaround is dilution. Ideally the undiluted product is screened, but where ingredients interfere the sample is diluted until the interference stops. There is a ceiling on that, called the maximum valid dilution, which is the dilution at which the limit would still be detectable.

The agency is explicit that the ceiling is not the working setting. The maximum valid dilution should not be the regular testing dilution. It recommends finding the lowest dilution that neutralizes the interference and screening just above that, then running a full enumeration if anything is detected.

Handling matters for the same reason. The ability to detect endotoxins can be affected by storage and handling, so procedures for both are supposed to rest on data showing that the measurable endotoxin content is stable.

The consequence for a reader is a question rather than a verdict. A result produced at a heavy dilution is a weaker measurement than one produced near the undiluted product, and the dilution is part of the result.

A passing batch can be a few vials averaged

Finished units may be combined before testing, and the rules around that are worth knowing because the practice is invisible on a certificate.

Units of an aqueous product can be pooled into one composite sample. Because pooling can dilute a container holding a harmful level with containers holding less, the maximum valid dilution has to be adjusted downward: divided by the number of samples being pooled.

The agency suggests no more than three units per composite, in keeping with the idea of testing containers from the beginning, middle and end of a run. It recommends the composite be made from aliquots removed aseptically after vigorous mixing, so the original containers survive for retesting if the pooled result comes back out of specification.

Some things should not be pooled at all. Products with an already low maximum valid dilution, products made as a suspension, and in-process samples taken from different stages of manufacture.

None of that is a criticism of pooling. It is the reason a result describes a batch rather than the vial in your hand, which is a distinction certificates rarely make.

What a failure is supposed to trigger

A quality claim is only as good as what happens when a test fails, and here the guidance is specific.

Where a failure occurred below the maximum valid dilution, the test should be repeated at a greater dilution that still does not exceed that ceiling. The failure itself has to be recorded in the laboratory results rather than replaced by the retest.

Where the test was performed at the maximum valid dilution and returned an out-of-specification result that cannot be attributed to a testing error, the lot should be rejected.

And the rules for retesting have to be written down in advance, in standard operating procedures approved by the firm's quality control unit. Deciding after the fact how many repeats are allowed is the thing that structure exists to prevent.

An endotoxin result is not a pyrogen result

The older method is a live-animal test, and it has not been retired, which tells you something about what the newer one covers.

For drugs, a firm may substitute an endotoxin test or an alternative cell-based test where it can demonstrate equivalent pyrogen detection. But the agency names two situations where the animal test is the more appropriate choice.

The first is where a risk assessment indicates that non-endotoxin pyrogens may be present. The second is where the assay's interference cannot be mitigated by dilution up to the ceiling, or by another validated preparation method.

One regulation still requires the animal test by name, and its scope is narrow. It applies to products covered by an approved biologics license, testing each lot of final containers of a product intended for injection, with a list of excepted product types. That is a rule for licensed biological products, not for a compounded preparation.

The takeaway is a limit on what a clean endotoxin result says. It says the endotoxin measurement came back within its limit. It is not a statement that nothing in the container can cause a fever.

What this guidance is, and what it is not

The document behind most of this article says plainly what it is worth, and repeating that is part of reading it honestly.

It states that FDA guidance documents do not establish legally enforceable responsibilities, that they describe the agency's current thinking, and that should means recommended rather than required. It is addressed to biological product, drug and device firms, and it assumes the reader already knows the compendial procedures it supplements.

The binding piece is much shorter. A batch of drug product purporting to be sterile or pyrogen-free has to be tested against those requirements, under written procedures. Which compounders are held to that regulation depends on which part of the compounding statute a facility operates under, and that comparison is covered separately here.

So the guidance is a reference point rather than a rule anyone in this market has broken. It describes what a serious endotoxin conversation contains, which is the standard a voluntary claim can be read against.

Reading a published endotoxin result

Look for the limit beside the number. A result with no limit printed next to it cannot be judged, because the limit depends on the amount given.

Look for the lot. A result describes one batch, and it speaks about your container only if the identifiers agree.

Look for the method and the dilution. Both change what the assay could have seen, and the guidance treats the dilution as part of the result rather than a detail.

Notice whether sterility and endotoxin are reported separately. They are two tests answering two questions, and a single line saying tested covers neither.

Notice what a chapter number is doing. Citing the procedure a laboratory followed is useful, and it is not the same as publishing what the procedure returned.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Guidance for Industry: Pyrogen and Endotoxins Testing — Questions and Answers (Edition 2), covering sampling, retesting, pooling and the withdrawal of the 1987 endotoxins limit table — U.S. Food and Drug Administration, March 2026
2. Pyrogen and Endotoxins Testing: Questions and Answers — guidance document landing page, level 2 revised, content current as of March 2026 — U.S. Food and Drug Administration, March 2026
3. 21 CFR 211.167, Special testing requirements, requiring appropriate laboratory testing for each batch of drug product purporting to be sterile and or pyrogen-free, under written procedures — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
4. 21 CFR 610.13, Purity, whose paragraph (b) requires a test for pyrogenic substances on each lot of final containers of a product intended for injection under an approved biologics license application — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026